About the Company
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALKS News
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and ...
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
Alkermes plc (NASDAQ:ALKS) revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts ...
Alkermes' Innovations Are Transforming Mental Health Treatments
In addition to Vivitrol, which will be discussed in more detail later, we also highlight Lybalvi (olanzapine and samidorphan) ...
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the ...
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Alkermes plc ALKS announced positive top-line data from a phase Ib study evaluating its novel, investigational, oral orexin 2 receptor (OX2R) agonist, ALKS 2680, as a once-daily treatment for ...
Alkermes plc: Collecting The Fruits Of The 2023 Spinoff
Alkermes' spinoff transaction with Mural Oncology resulted in cost cutting and higher EBITDA margins. Read why I'm bullish on ALKS stock.
Alkermes PLC
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Alkermes Stock (NASDAQ:ALKS), Analyst Ratings, Price Targets, Predictions
$24.99 28.05% HC Wainwright & Co.
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
On Tuesday, Alkermes plc (NASDAQ:ALKS) revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680 ...
Loading the latest forecasts...